Clinical and laboratory features of 18 patients with SSc aCL+ and/or aβ2GPI+
| aβ2GPI* | aCL* | |||||||
|---|---|---|---|---|---|---|---|---|
| Sex, age, subset of SSc | IgG (OD) | IgM (OD) | IgG (GPL) | IgM (MPL) | Thromboses | Pregnancy loss | Other clinical and laboratory features | Antithrombotic treatment |
| *Normal values: aβ2GPI IgG <0.13, IgM <0.28; aCL IgG <10, IgM <10. | ||||||||
| SLE, systemic lupus erythematosus; LAC, lupus anticoagulant; DVT, deep vein thrombosis; PBC, primary biliary cirrhosis; PM, polymyositis. | ||||||||
| F, 37, l | 1.68 | 0.36 | 67 | 35 | No | No | Overlap SLE, LAC− | Aspirin |
| F, 55, d | 0.38 | Neg | Neg | Neg | No | No | Aspirin | |
| F, 57, l | Neg | 2.11 | Neg | Neg | DVT | 2 Miscarriages | Livedo reticularis, LAC− | Warfarin |
| F, 61, l | Neg | 0.84 | Neg | Neg | No | No | PBC, LAC− | Aspirin |
| F, 54, l | Neg | 0.66 | Neg | Neg | No | 1 Miscarriage, 1 intrauterine death | Aspirin | |
| F, 64, l | Neg | 0.58 | Neg | Neg | No | No | LAC− | Aspirin |
| M, 65, l | Neg | 0.53 | 13 | Neg | Subclavian artery | Non-erosive arthritis, LAC− | Ticlopidine | |
| F, 76, l | Neg | 0.43 | Neg | 15 | Recurrent DVT in leg | No | Aspirin | |
| F, 59, l | Neg | 0.42 | Neg | 15 | No | No | Pulmonary hypertension | Warfarin + iloprost |
| F, 63, l | Neg | 0.38 | Neg | Neg | No | No | Superficial phlebitis | Aspirin |
| F, 78, l | Neg | 0.35 | Neg | Neg | No | No | Aspirin | |
| F, 43, l | Neg | 0.32 | Neg | Neg | No | No | Aspirin | |
| F, 59, l | Neg | 0.31 | Neg | Neg | No | No | Overlap PM/SLE, LAC− | Aspirin |
| F, 60, l | Neg | 0.30 | Neg | Neg | No | No | No | |
| F, 65, l | Neg | Neg | 30 | Neg | Myocardial infarction | No | Pulmonary hypertension, encephalopathy, LAC+ | Warfarin + iloprost |
| F, 37, d | Neg | Neg | 18 | Neg | Saphenous vein thrombosis | No | Overlap SLE | Aspirin |
| F, 54, l | Neg | Neg | 20 | Neg | No | No | Aspirin | |
| F, 52, d | Neg | Neg | Neg | 10.7 | No | No | Aspirin | |